Argenica Therapeutics Limited announced the appointment of experienced healthcare and clinical trials professional Dr. Meghan Thomas, as Head of Clinical Development. Dr. Thomas will join Argenica in its Perth office in early April and provide leadership, project management and program oversight for the timely preparation and execution of the Company's upcoming Phase 1 clinical trial program. Dr. Thomas will also manage the Company's future clinical trials as Argenica moves into later stage clinical development.

Dr. Thomas has significant experience in managing clinical trials, and joins Argenica from Zelira Therapeutics Ltd. (ASX:ZLD) where she was Vice President of Clinical Programs and Operations. In this role, Dr. Thomas was responsible for overseeing the clinical trial program, Australian commercial manufacturing operations, and the regulatory affairs requirements to progress Zelira's lead therapies through to commercialisation. Prior to joining Zelira, Dr. Thomas worked in Clinical Planning and with Human Research Ethics Committees across Government Health Departments in Perth, Western Australia.